BH17 Bridging the Gap: Identifying Dual-Targeting Therapies for Patients with Alopecia Areata and Coexisting Immune-Mediated Inflammatory Diseases

The study explores the potential for dual-targeting therapies in treating alopecia areata (AA) alongside other immune-mediated inflammatory diseases (IMIDs) like Crohn's disease and atopic dermatitis. It highlights the limited number of drugs approved for AA and reviews current and emerging therapies, particularly focusing on Janus kinase inhibitors such as baricitinib and upadacitinib, which show promise for both AA and other IMIDs. The study also discusses the potential of abatacept, a CTLA4 modulator, in treating AA. The authors emphasize the importance of cross-specialty collaboration and real-world evidence through registries like the Global Registry of Alopecia areata disease Severity and treatment Safety (GRASS) UK to improve patient care and outcomes.